Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong

Table 3 QALY gained and cost savings of QIV versus TIV

Year	QALYs	Direct cost	Indirect cost	Total cost
Age 65–79 years
2001	0.199	1,781	543	2,324
2002*	0	0	0	0
2003	0.291	2,600	792	3,392
2004	21.940	196,311	59,816	256,127
2005	6.670	59,679	18,184	77,863
2006	2.210	19,777	6,026	25,803
2007	22.826	204,241	62,232	266,473
2008	16.370	146,474	44,631	191,105
2010	4.785	42,818	13,047	55,864
Age ≥80 years
2001	0.023	314	96	410
2002*	0	0	0	0
2003	0.581	7,880	2,401	10,281
2004	12.372	167,723	51,105	218,829
2005	3.207	43,477	13,247	56,724
2006	0.829	11,234	3,423	14,657
2007	27.335	370,553	112,907	483,461
2008	19.455	263,741	80,362	344,103
2010	7.425	100,651	30,668	131,319

*In 2002, no influenza B virus was identified from patients admitted to the Prince of Wale Hospital for age groups 65–79 years and ≥80 years. The expected reductions in infected cases, cost-saving and additional QALYs gained with QIV were considered as zero.

ISSN: 1471-2334